<DOC>
	<DOCNO>NCT02046174</DOCNO>
	<brief_summary>This clinical research study investigational ( FDA IND-BB 10091 ) treatment patient advance colorectal cancer longer respond standard therapy . The treatment evaluate effect tumor growth . It consist placement ( implantation ) small bead contain mouse renal adenocarcinoma cell ( RENCA macrobeads ) . The cell macrobeads produce substance show slow stop growth tumor experimental animal veterinary patient . It test 31 human subject different type cancer Phase I safety trial . Phase II study patient colorectal , pancreatic prostate cancer progress</brief_summary>
	<brief_title>Nonrandomized , Open-Label Phase IIb Efficacy Trial Cancer Macrobeads Compared With Best Supportive Care Patients With Treatment-Resistant Colorectal Cancer</brief_title>
	<detailed_description>This Phase IIb , multicenter , nonrandomized , open-label study RENCA macrobeads patient treatment-resistant , metastatic colorectal carcinoma determine effect RENCA macrobead implantation overall survival compare best supportive care . Two treatment group enrol study , follow : - Group A ( n=40 ) - patient undergo 4 implantation RENCA macrobeads , amount 8 RENCA macrobeads /kg body weight - Group B ( n=80 ) - patient receive receive best supportive care , define management symptom aim maintain improve quality life , include approved therapy target patient 's malignancy</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients treatment group must meet follow criterion consider eligible participate study : Adult men woman , age 18 year old , histologicallyconfirmed , metastatic adenocarcinoma colon rectum resistant available treatment option Radiographically document evidence disease progression . Life expectancy least 6 week , investigator 's opinion , time disease progression document . Considered surgical candidate basis comorbidity risk , number site metastasis , ability withstand general anesthesia . Able provide write informed consent . Patients Group A must also meet follow additional criterion : ECOG performance status score 0 , 1 , 2 . Adequate hematologic function , define follow : 1. absolute neutrophil count ( ANC ) ≥1500 /mL 2. hemoglobin ≥9 g/dL 3. platelet ≥75,000 /mL Adequate hepatic function , define follow : 1. bilirubin ≤1.5 time upper limit normal ( x ULN ) 2. aspartate transaminase ( AST ) ≤3 x ULN , ≤5 x ULN liver metastases present 3. alanine transaminase ( ALT ) ≤3 , x ULN , ≤5 x ULN liver metastases present Adequate renal function , define creatinine ≤2.0 mg/dL . Adequate coagulation function , define follow : 1. International Normalized Ratio ( INR ) ≤1.5 2 3 patient receive anticoagulation 2. partial thromboplastin time ( PTT ) ≤5 second ULN Note : Patients receive fulldose anticoagulation therapy must receive stable dose oral anticoagulant therapy lowmolecularweight heparin . Clinically significant toxic effect chemotherapy ( exclude alopecia ) , radiotherapy , hormonal therapy , prior surgery must resolve Grade 1 good , exception peripheral neuropathy , must resolve Grade 2 better . Agrees contraceptive use study sexually active Patients either treatment group meet follow criterion exclude participate study : Hepatic blood flow abnormality , i.e. , portal vein hypertension thrombosis , and/or large volume ascites . Concurrent cancer type , except skin cancer melanoma . A positive test result HIV hepatitis A screening . Considered investigator unsuitable participation study Patients Group A meet follow criterion exclude participate study : Received FDAapproved chemotherapy within 3 week Day 0 , bevacizumab ( similar drug ) within 4 week Day 0 , radiation therapy site within 4 week Day 0 Investigational anticancer therapy within 4 week Day 0 Positive reaction skin test allergy mouse antigen History hypersensitivity reaction , opinion investigator , pose increase risk allergic reaction RENCA macrobeads , particularly know allergy murine antigens body tissue . Ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia ( exception well control atrial fibrillation ) , active bleeding , psychiatric illness , social situation could interfere patient 's ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>colon</keyword>
	<keyword>colorectal</keyword>
	<keyword>rectal</keyword>
	<keyword>cancer</keyword>
	<keyword>macrobead</keyword>
	<keyword>stage IV</keyword>
	<keyword>metastatic</keyword>
	<keyword>biological</keyword>
	<keyword>mouse cell</keyword>
	<keyword>new york</keyword>
	<keyword>new jersey</keyword>
	<keyword>clinical research</keyword>
</DOC>